Effects of the selective estrogen receptor modulators for the treatment of male infertility: a systematic review and meta-analysis

Reference

• Agarwal A, Mulgund A, Hamada A, et al. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37.
   PubMed Web of Science ®Google Scholar
• Valenti D, La Vignera S, Condorelli RA, et al. Follicle-stimulating hormone treatment in normogonadotropic infertile men. Nat Rev Urol. 2013;10:55–62.
   PubMed Web of Science ®Google Scholar
• Duca Y, Calogero AE, Cannarella R, et al. Current and emerging medical therapeutic agents for idiopathic male infertility. Expert Opin Pharmacother. 2018;8:1–13.
   Google Scholar
• Plouffe L Jr, Siddhanti S. The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis. Ann N Y Acad Sci. 2001;949:251–258.
   PubMed Web of Science ®Google Scholar
• Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol. 2006;176:1307–1312.
   PubMed Web of Science ®Google Scholar
• Cocuzza M, Agarwal A. Nonsurgical treatment of male infertility: specific and empiric therapy. Biologics. 2007;1:259–269.
   PubMedGoogle Scholar
• Vandekerckhove P, Lilford R, Vail A, et al. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2000;(2):CD000151.
   PubMedGoogle Scholar
• Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013;1(5):749–757.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses. 2012. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Wang C, Chan CW, Wong KK, et al. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril. 1983;40(3):358–365.
   PubMed Web of Science ®Google Scholar
• Wang C, Chan SY, Tang LC, et al. Clomiphene citrate does not improve spermatozoal fertilizing capacity in idiopathic oligospermia. Fertil Steril. 1985;44(1):102–105.
   PubMed Web of Science ®Google Scholar
• Török L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia. 1985;17(5):497–501.
   PubMed Web of Science ®Google Scholar
• AinMelk Y, Belisle S, Carmel M, et al. Tamoxifen citrate therapy in male infertility. Fertil Steril. 1987;48(1):113–117.
   PubMed Web of Science ®Google Scholar
• Homonnai ZT, Yavetz H, Yogev L, et al. Clomiphene citrate treatment in oligozoospermia: comparison between two regimens of low-dose treatment. Fertil Steril. 1988;50(5):801–804.
   PubMed Web of Science ®Google Scholar
• Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen – a randomized controlled study. Int J Androl. 1992;15(1):14–18.
   PubMedGoogle Scholar
• Sterzik K, Rosenbusch B, Mogck J, et al. Tamoxifen treatment of oligozoospermia: a re-evaluation of its effects including additional sperm function tests. Arch Gynecol Obstet. 1993;252(3):143–147.
   PubMed Web of Science ®Google Scholar
• Kotoulas IG, Cardamakis E, Michopoulos J, et al. Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fertil Steril. 1994;61(5):911–914.
   PubMed Web of Science ®Google Scholar
• Adamopoulos DA, Nicopoulou S, Kapolla N, et al. Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. Fertil Steril. 1995;64(4):818–824.
   PubMed Web of Science ®Google Scholar
• Adamopoulos DA, Nicopoulou S, Kapolla N, et al. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril. 1997;67(4):756–762.
   PubMed Web of Science ®Google Scholar
• Matsumiya K, Kitamura M, Kishikawa H, et al. A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Int J Urol. 1998;5(4):361–363.
   PubMedGoogle Scholar
• Kadioglu TC, Köksal IT, Tunç M, et al. Treatment of idiopathic and postvaricocelectomy oligozoospermia with oral tamoxifen citrate. BJU Int. 1999;83(6):646–648.
   PubMed Web of Science ®Google Scholar
• Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal. Int Urol Nephrol. 2009;41(4):773–776.
   PubMed Web of Science ®Google Scholar
• Moradi M, Moradi A, Alemi M, et al. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J. 2010;7(3):188–193.
   PubMed Web of Science ®Google Scholar
• Guo L, Jing J, Feng YM, et al. Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia. Int Urol Nephrol. 2015;47(9):1463–1469.
   PubMed Web of Science ®Google Scholar
• ElSheikh MG, Hosny MB, Elshenoufy A, et al. Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: a prospective, randomized trial. Andrology. 2015;3(5):864–867.
   PubMed Web of Science ®Google Scholar
• Damber JE, Abramsson L, Duchek M. Tamoxifen treatment of idiopathic oligozoospermia: effect on hCG-induced testicular steroidogenesis and semen variables. Scand J Urol Nephrol. 1989;23(4):241–246.
   PubMed Web of Science ®Google Scholar
• Rozati R, Reddy PP, Reddanna P, et al. Role of environmental estrogens in the deterioration of male factor fertility. Fertil Steril. 2002;78(6):1187–1194.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–629.
   PubMed Web of Science ®Google Scholar
• Rönnberg L. The effect of clomiphene citrate on different sperm parameters and serum hormone levels in preselected infertile men: a controlled double-blind cross-over study. Int J Androl. 1980;3(5):479–486.
   PubMedGoogle Scholar
• Cakan M, Aldemir M, Topcuoglu M, et al. Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men. Urol Int. 2009;83(4):446–451.
   PubMed Web of Science ®Google Scholar
• Buvat J, Ardaens K, Lemaire A, et al. Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil Steril. 1983;39(5):700–703.
   PubMed Web of Science ®Google Scholar
• Tsourdi E, Kourtis A, Farmakiotis D, et al. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril. 2009;91(4):1427–1430.
   PubMed Web of Science ®Google Scholar
• Höbarth K, Lunglmayr G, Kratzik C. Effect of tamoxifen and kallikrein on sperm parameters including hypoosmotic swelling test in subfertile males. A retrospective analysis. Andrologia. 1990;22(6):513–517.
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Farmakis C, Rousso D, et al. The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril. 2007;88(4):847–853.
   PubMed Web of Science ®Google Scholar
• Nada EA, El Taieb MA, Ibrahim HM, et al. Efficacy of tamoxifen and l-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia. Andrologia. 2015;47(7):801–810.
   PubMed Web of Science ®Google Scholar
• Lanzafame FM, La Vignera S, Vicari E, et al. Oxidative stress and medical antioxidant treatment in male infertility. Reprod Biomed Online. 2009;19(5):638–659.
   PubMed Web of Science ®Google Scholar
• Showell MG, Brown J, Yazdani A, et al. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2011;19:CD007411.
   Google Scholar
• Mongioi L, Calogero AE, Vicari E, et al. The role of carnitine in male infertility. Andrology. 2016;4(5):800–807.
   PubMed Web of Science ®Google Scholar